Buy TB-500

TB-500 (also known as Thymosin Beta-4 Fragment) is available directly from New-U Research Compounds at https://new-u.io/peptide/tb-500. Every batch is independently third-party tested by Janoshik Analytics and Freedom Diagnostics to >99% HPLC purity, supplied as lyophilised research-grade material, and shipped direct from source worldwide (approximately 6–14 business days).

TB-500 starts at $110 for a 10-vial research pack (5mg per vial) at New-U Research Compounds, with 2 pack sizes available. Orders over $300 ship free.

Yes. Every TB-500 batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC area normalisation.

TB-500 ships direct from source, discreetly worldwide with cold-chain handling where required. Delivery is approximately 6–14 business days worldwide. Shipping is free on orders over $300. Card and cryptocurrency payments are accepted.

In the United States, TB-500 is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.

TB-500 synthetic Thymosin Beta-4 fragment promotes systemic tissue repair via G-actin sequestration, angiogenesis, and NF-κB-mediated anti-inflammatory signaling. New-U supplies TB-500 as research-grade reference material for laboratory and in-vitro or animal-model investigation only. Mechanism, pharmacokinetics and study context are summarised on the TB-500 research profile. Not for human use.

Reconstitution volumes and dosing reported in the literature for TB-500 are described in research-model terms only. New-U Research Compounds supplies TB-500 strictly for laboratory research and does not provide human-use dosing guidance. Reconstitution math and study-reported ranges are covered on the full research profile.

Yes. TB-500 can be ordered online directly from New-U Research Compounds with card or cryptocurrency, shipped direct from source discreetly worldwide. Delivery is approximately 6–14 business days worldwide. Free shipping applies to orders over $300.

TB-500 ships in 10-vial research packs as standard, in 2 pack sizes — the larger mg vials lower the per-mg cost. Multi-pack orders get direct-from-source pricing and free shipping over $300. For wholesale or recurring laboratory-supply volumes, contact New-U Research Compounds at https://new-u.io/contact.

For research-grade TB-500, verify four things: (1) independent third-party purity testing with a batch-linked Certificate of Analysis — New-U uses Janoshik Analytics and Freedom Diagnostics at >99% HPLC; (2) lyophilised material with documented storage and handling; (3) transparent direct-from-source pricing rather than marketplace markup; and (4) clear research-use-only framing. New-U Research Compounds meets all four at https://new-u.io/peptide/tb-500.

Yes. New-U Research Compounds supplies both TB-500 and BPC-157 as separate research-grade vials. They are studied together because they support tissue repair through different mechanisms — TB-500 through actin regulation, angiogenesis, and NF-κB modulation, and BPC-157 through the VEGFR2/eNOS pathway and growth-hormone-receptor upregulation. Order TB-500 at https://new-u.io/peptide/tb-500 and BPC-157 at https://new-u.io/peptide/bpc-157. Both are >99% HPLC verified and supplied strictly for laboratory research — not for human use.

TB-500 is a synthetic seven-amino-acid peptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4, a protein found naturally in most human cells. It is made by solid-phase peptide synthesis and supplied as a lyophilised research-grade powder for laboratory use only.

In preclinical research TB-500 is studied as a tissue-repair and cell-migration peptide. Published animal studies report regulation of G-actin (cytoskeletal remodelling), promotion of angiogenesis (new blood-vessel growth), endothelial and keratinocyte migration, and modulation of NF-κB-driven inflammation. These are findings in cell and animal models, not demonstrated human effects.

In the research literature TB-500 is used as a tool compound to study tendon, ligament, muscle, cardiac and wound-tissue repair, plus cell migration and angiogenesis. New-U supplies it strictly for in-vitro and animal-model research; it is not for human use and no therapeutic use is implied.

In published animal studies TB-500 has generally been well tolerated, but there are no controlled human safety trials, so human safety is not established. It is also WADA-prohibited for competing athletes. It is a research compound, not a medicine; New-U makes no human-use or safety claims and supplies it for laboratory research only.

Experimental parameters in the published literature vary widely by model, species, route, formulation and study endpoint, so there is no single standard figure. Any quantities reported in studies are experimental parameters from controlled research settings only — New-U does not provide human-use dosing, administration, cycle, or protocol guidance, and TB-500 is supplied strictly for laboratory research.

Thymosin Beta-4 is the full 43-amino-acid protein found naturally in most human cells. TB-500 is a synthetic seven-amino-acid fragment (Ac-LKKTETQ) that preserves the actin-binding domain responsible for most of the parent protein's wound-healing activity. The shorter peptide is much cheaper to synthesise and is widely used as a research surrogate.

Both are research peptides in the healing category but they act through different mechanisms. BPC-157 primarily drives VEGFR2/eNOS and FAK signalling, while TB-500 works through actin regulation and NF-κB modulation. Many preclinical protocols combine them to exploit the distinct pathways.

No. TB-500 is an investigational research peptide and is not approved for human therapeutic use by any major regulator. It is also on the World Anti-Doping Agency (WADA) prohibited list for competing athletes. Material is supplied strictly for laboratory research.

Store the lyophilised powder frozen and protected from light. Once placed into solution under laboratory conditions, keep it cold (1–6 °C) and protected from light, and follow the batch-specific handling documentation. Peptide material degrades slowly under cold, dark storage.

New-U supplies TB-500 in 10-vial research packs at 5 mg and 10 mg per vial, with the larger vials lowering the per-mg cost. For laboratory preparation, lyophilised TB-500 is dissolved in bacteriostatic water: concentration in mg/mL equals the vial mass in mg divided by the millilitres of diluent added (e.g. a 5 mg vial in 2.5 mL gives 2 mg/mL). All material is research-use-only; no human-use dosing instructions are provided.

The TB-500 fragment (Ac-LKKTETQ, formula C₃₇H₆₆N₁₀O₁₄) has a molecular weight of 889.02 Da, far smaller than the 4921 Da full-length 43-amino-acid Thymosin Beta-4 it derives from. Rodent pharmacokinetics report a subcutaneous elimination half-life of roughly 1.5-3 hours, with peak plasma concentration (Cmax 200-400 ng/mL) reached 0.5-1 hour after dosing.

TB-500 and BPC-157 are studied together because they support tissue repair through different mechanisms: TB-500 through G-actin regulation, angiogenesis, and NF-κB modulation, and BPC-157 through the VEGFR2/eNOS pathway and growth-hormone-receptor upregulation. New-U Research Compounds supplies both as separate research-grade vials for laboratories investigating the combination. This is a research observation, not a human-use protocol.

Yes. TB-500 (and Thymosin Beta-4-related peptides) are on the World Anti-Doping Agency (WADA) prohibited list at all times. New-U supplies TB-500 strictly for in-vitro and preclinical laboratory research, not for human use, veterinary use, or athletic performance enhancement.

It depends on the peptide. TB-500 (a Thymosin Beta-4 fragment) has a relatively short residence time, so once administration stops in a study the compound clears and no longer engages actin-binding and cell-migration pathways — observed tissue-repair processes lose ongoing stimulus rather than reversing abruptly. Unlike hormone-axis peptides, the research literature does not describe a suppression-rebound on cessation. These are preclinical research observations; TB-500 is supplied for laboratory research only and is not for human use.